CTOs on the Move

FLX Bio

www.flxbio.com

 
FLX Bio, Inc. is a biotechnology company focused on the discovery and development of novel therapies that will improve and prolong the lives of people with cancer. The company is targeting key cancer pathways with its clinical-stage program, FLX925, and building a pipeline of immuno-oncology oral medicines designed to activate a patient`s own immune system to eradicate cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.flxbio.com
  • 561 Eccles Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.489.9000

Executives

Name Title Contact Details

Funding

FLX Bio raised $50M on 04/26/2016
FLX Bio raised $60M on 12/21/2017
FLX Bio raised $37M on 06/18/2019

Similar Companies

GlycoMimetics

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.

New Century Hospice

New Century Hospice is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Syreon Corporation

Syreon Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stelexis Therapeutics

Stelexis` mission is to become the leading cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Glyscend

Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.